News

Jessica Nickrand, PhD, and Allyson Eyermann from the Child Neurology Foundation emphasized the importance of multidisciplinary collaboration for children with epilepsy and their families.

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Depobam Samanta, MD, MS, FAAP, FAES. [LISTEN TIME: 25 minutes]

In the phase 2/3 DEVOTE study, a higher dose of nusinersen met its primary end point at 6 months, achieving a statistically significant improvement in motor function among treatment-naïve symptomatic infants with SMA.

The medical director of the Arkansas Children’s Comprehensive Epilepsy Program provided commentary on patient selection and personalized treatment approaches when using neuromodulation devices for Lennox-Gastaut syndrome. [WATCH TIME: 3 minutes]

Leah Blank, MD, an assistant professor of neurology, population health, science, and policy at the Icahn School of Medicine provided commentary on some of the experience and positive movement from the 2024 American Epilepsy Society Annual Meeting.

At ECTRIMS 2024, the postdoctoral research assistant at Charité University Berlin discussed how the updated diagnostic criteria aim to address gaps in diagnosing and treating overlapping autoimmune conditions. [WATCH TIME: 4 minutes]

Between patients treated with anti-CGRP targeting treatments and onabotulinumtoxinA, there were no increased risk of composite CVD events, hypertensive crisis, peripheral revascularization, or Raynaud phenomenon.

The neurointensivist and assistant professor of neurology at Boston Medical Center provided insight on a 2024 paper that defined consensus entrustable professional activities for neurocritical care advanced practice providers. [WATCH TIME: 5 minutes]

The PoNSTEP study demonstrated significant gait improvement with PoNS Therapy, showing a mean DGI increase of 5.0 at week 14, adherence-related gains during Phase 2, and sustained benefits for most participants six months post-treatment.

Take a look at some of the most-anticipated FDA pending approvals expected in 2025 that researchers and clinicians in neurology should keep an eye out on.

The professor of neurology at NYU Grossman School of Medicine talked about using responsive neurostimulators to seek shortened drug evaluation timelines and enhance epilepsy treatment.

The study highlighted tofersen's potential to slow ALS progression in patients with SOD1 mutations, showing reduced neurofilament levels, functional stabilization, and improved muscle strength, despite mild to moderate adverse events.

Robert Rothrock, MD, a spinal neurosurgeon at Baptist Health Miami Neuroscience Institute, provided commentary on key topics in spine health amid the 2025 Baptist Health Spine Symposium.

The assistant professor at The Hebrew University of Jerusalem School of Pharmacy discussed how the brain microbiome may contribute to Alzheimer through interactions with immune responses and proteins. [WATCH TIME: 5 minutes]

A 51-year-old patient with neuromyelitis optica spectrum disorder and hemorrhagic longitudinally extensive transverse myelitis presented a challenging case.

The professor and chair of the Department of Molecular Pathobiology at NYU College of Dentistry discussed how a recently published preclinical study adds to the understanding of neuropilin-1 in chronic pain. [WATCH TIME: 3 minutes]

These findings underscore the potential of advanced imaging technologies to detect subtle gray matter differences, aiding in the accurate differentiation between MS and NMOSD.

At ECTRIMS 2024, the assistant professor at the University of Naples the latest multiple sclerosis diagnostic criteria, which emphasized a shift toward biologically based diagnoses. [WATCH TIME: 4 minutes]

A new study highlighted the importance of initiating immunotherapy promptly in chronic inflammatory demyelinating polyneuropathy to prevent axonal damage and disability progression.

At the 2024 ECTRIMS Congress, the neurologist at the University Hospital Center of Nice talked about how the decision to treat patients at risk of MS is highly individualized. [WATCH TIME: 3 minutes]

Here's some of what is coming soon to NeurologyLive® this week.

A study highlighted corneal confocal microscopy as a promising noninvasive tool for tracking sensory nerve damage in chronic inflammatory demyelinating polyradiculoneuropathy.

At ECTRIMS 2024, the consultant neurologist at Queen's Square MS Center in London talked about the evolving McDonald criteria to define multiple sclerosis biologically. [WATCH TIME: 5 minutes]

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on tuberous sclerosis complex (TSC).

A new study suggests particulate matter exposure exacerbated the severity of multiple sclerosis and neuromyelitis optica spectrum disorder, with significant clinical and radiological impacts.

Nipocalimab’s biologics license application is supported by the phase 3 Vivacity-MG3 trial, in which the agent demonstrated superiority over placebo plus standard-of-care over a 24-week period.

Neurology News Network. for the week ending January 18, 2025. [WATCH TIME: 4 minutes]

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending January 17, 2024.